Cases & Deals

  • Home
  • Practices
  • AbbVie prevails in Sandoz IPR challenge of HUMIRA® formulation patent

Share

AbbVie prevails in Sandoz IPR challenge of HUMIRA® formulation patent

February 2018

Client(s) AbbVie Inc.

Jones Day served as lead counsel and successfully defended AbbVie in connection with an inter partes review (IPR) petition filed by Sandoz, Inc. against U.S. Patent No. 8,802,100, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®. Sandoz is developing a biosimilar version of HUMIRA®, which is the top selling drug in the world. Following the filing of the Patent Owner's Preliminary Response by AbbVie, the PTAB denied institution of Sandoz's IPR petition with regard to all of the challenged claims.

Sandoz Inc. v. AbbVie Biotechnology Ltd., IPR2017-01823 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.